<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="73856">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01891643</url>
  </required_header>
  <id_info>
    <org_study_id>CA204-006 (Biomarker Substudy)</org_study_id>
    <secondary_id>2010-022445-20</secondary_id>
    <nct_id>NCT01891643</nct_id>
  </id_info>
  <brief_title>PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy)</brief_title>
  <official_title>A Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects With Previously Untreated Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <authority>Australia: Department of Health and Ageing Therapeutic Goods Administration</authority>
    <authority>Australia: National Health and Medical Research Council</authority>
    <authority>Austria: Federal Office for Safety in Health Care</authority>
    <authority>Belgium: The Federal Public Service (FPS) Health, Food Chain Safety and Environment</authority>
    <authority>Canada: Health Canada</authority>
    <authority>Czech Republic: State Institute for Drug Control</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Germany: Paul-Ehrlich-Institut</authority>
    <authority>Germany: Federal Office for Radiation Protection</authority>
    <authority>Germany: Ministry of Health</authority>
    <authority>Greece: Ethics Committee</authority>
    <authority>Greece: National Organization of Medicines</authority>
    <authority>Hungary: National Institute of Pharmacy</authority>
    <authority>Ireland: Irish Medicines Board</authority>
    <authority>Israel: Israeli Health Ministry Pharmaceutical Administration</authority>
    <authority>Italy: Ministry of Health</authority>
    <authority>Italy: National Bioethics Committee</authority>
    <authority>Italy: National Institute of Health</authority>
    <authority>Italy: National Monitoring Centre for Clinical Trials - Ministry of Health</authority>
    <authority>Italy: The Italian Medicines Agency</authority>
    <authority>Poland: National Institute of Medicines</authority>
    <authority>Poland: Ministry of Health</authority>
    <authority>Poland: Ministry of Science and Higher Education</authority>
    <authority>Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products</authority>
    <authority>Romania: National Medicines Agency</authority>
    <authority>Russia: Ethics Committee</authority>
    <authority>Russia: Ministry of Health of the Russian Federation</authority>
    <authority>Russia: FSI Scientific Center of Expertise of Medical Application</authority>
    <authority>Spain: Spanish Agency of Medicines</authority>
    <authority>Switzerland: Federal Office of Public Health</authority>
    <authority>Switzerland: Swissmedic</authority>
    <authority>Turkey: Ministry of Health</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to look at subjects who receive Lenalidomide, Dexamethasone, and
      Elotuzumab and determine if they will have lower surface CS1 expression on malignant plasma
      cells at the time of progression than those who receive Lenalidomide and Dexamethasone
      without Elotuzumab
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">August 2016</completion_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Change from baseline to progression of the cell surface expression of CS1 from bone marrow-derived MM cells in both treatment arms</measure>
    <time_frame>Screening (up to 30 days prior to first dose) and time of progression (33 months)</time_frame>
    <safety_issue>No</safety_issue>
    <description>CS1=CD-2 subset 1
MM=Multiple Myeloma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Level of cell surface CS1 from bone marrow-derived MM cells in both treatment arms</measure>
    <time_frame>Time of progression (33 months)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sCS1 levels in serum and to evaluate change from baseline and during therapy and at progression in both treatment arms</measure>
    <time_frame>Screening (up to 30 days prior to first dose), Cycle 3 Day 1 and time of progression (33 months)</time_frame>
    <safety_issue>No</safety_issue>
    <description>sCS1=Soluble form of CS1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The presence, and the change from baseline, on therapy, and at progression, of circulating MM cell numbers and their CS1 cell surface expression in both treatment arms</measure>
    <time_frame>Screening (up to 30 days prior to first dose), Cycle 3 Day 1 and time of progression (33 months)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The cell number and CS1 expression patterns between matched samples of bone marrow-derived MM cells and circulating MM cells at baseline and at progression in both treatment arms</measure>
    <time_frame>Screening (up to 30 days prior to first dose) and time of progression (33 months)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">750</enrollment>
  <condition>Newly Diagnosed, Previously Untreated Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Arm 1: Lenalidomide + Dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lenalidomide 25 mg capsules by mouth once daily (on Days 1-21), repeat every 28 days until subject meets criteria for discontinuation of study drug
Dexamethasone 40 mg tablets by mouth weekly (on Days 1, 8, 15, 22), repeat every 28 days until subject meets criteria for discontinuation of study drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: Lenalidomide + Dexamethasone + Elotuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lenalidomide 25 mg capsules by mouth once daily (Days 1-21)
Dexamethasone 28 mg tablets by mouth once daily [Days 1, 8, 15, 22 (cycles 1 &amp; 2); Days 1 &amp; 15(cycles 3-18); Day 1 (cycle 19 &amp; beyond)]
Dexamethasone 40 mg tablets by mouth once daily [Days 8 &amp; 22 (cycles 3-18); Days 8, 15, 22 (cycle 19 &amp; beyond)]
Dexamethasone 8 mg IV (intravenous) solution once daily [Days 1, 8, 15, 22 (cycles 1 &amp; 2); Days 1 &amp; 15 (cycles 3-18); Day 1 (cycle 19 &amp; beyond)]
Elotuzumab 10 mg/kg IV solution weekly [Days 1, 8, 15, 22 (cycles 1 &amp; 2); Days 1 &amp; 15 (cycles 3-18)]
Elotuzumab 20 mg/kg IV solution on Day 1 (cycle 19 &amp; beyond)
Repeat above-mentioned dose cycles every 28 days until subject meets criteria for discontinuation of study drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <arm_group_label>Arm 1: Lenalidomide + Dexamethasone</arm_group_label>
    <arm_group_label>Arm 2: Lenalidomide + Dexamethasone + Elotuzumab</arm_group_label>
    <other_name>Revlimid®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <arm_group_label>Arm 1: Lenalidomide + Dexamethasone</arm_group_label>
    <arm_group_label>Arm 2: Lenalidomide + Dexamethasone + Elotuzumab</arm_group_label>
    <other_name>Decadron®</other_name>
    <other_name>Dexamethasone Intensol®</other_name>
    <other_name>Dexpak®</other_name>
    <other_name>Taperpak®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Elotuzumab</intervention_name>
    <arm_group_label>Arm 2: Lenalidomide + Dexamethasone + Elotuzumab</arm_group_label>
    <other_name>BMS-901608</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com.

        Inclusion Criteria:

        Subjects who are newly diagnosed with symptomatic MM and who:

          -  Have not received any prior systemic anti-myeloma therapy

          -  Have measurable disease

          -  And are not candidates for high-dose therapy plus stem-cell transplantation (SCT)
             because of age (≥65 years) or coexisting conditions. Refusal to undergo high dose
             therapy with SCT is NOT sufficient for entry onto CA204-006 for a subject &lt;65 years
             old. There must be a comorbidity that prevents SCT for a subject &lt;65 years old

        Exclusion Criteria:

          -  Subjects with non-secretory or oligo-secretory or free light-chain only myeloma

          -  Smoldering MM, defined as asymptomatic MM with absence of lytic bone lesions

          -  Monoclonal Gammopathy of Undetermined Significance (MGUS)

          -  Active plasma cell leukemia

          -  Known Human Immunodeficiency Virus (HIV) infection or active hepatitis A, B, or C
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>For participation information at a USA site use a phone number below. For Site information outside USA please email</last_name>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of email MUST contain NCT# &amp; Site#. Only trial site that are recruiting have contact information at this time</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Pacific Hematology Oncology Associates</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chrissy Raymundo, Site 7624</last_name>
      <phone>415-221-4810</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Cancer Institute</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deneise Francis, Site 7613</last_name>
      <phone>954-265-2796</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Illinois Cancercare, Pc</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61615</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Sachdev, Site 7606</last_name>
      <phone>309-243-3620</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Franciscan St. Francis Health</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Rubensetin, Site 7620</last_name>
      <phone>317-859-5252</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Crescent City Research Consortium, LLC</name>
      <address>
        <city>Marrero</city>
        <state>Louisiana</state>
        <zip>70072</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Guttierrez, Site 7614</last_name>
      <phone>504-883-2968</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Messer, Site 1638</last_name>
      <phone>614-366-4470</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University Of South Carolina Hollings Cancer Center</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shanta Salzer, Site 7615</last_name>
      <phone>843-792-1463</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baptist Cancer Center</name>
      <address>
        <city>Mephis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Dodd, Site 7628</last_name>
      <phone>901-226-1473</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northern Utah Associates</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <zip>84405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Kinsella, Site 7623</last_name>
      <phone>801-387-7166</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Athens</city>
        <zip>11528</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 4651</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 5050</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Rome</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 5056</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Chorzow</city>
        <zip>41-500</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 5252</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lublin</city>
        <zip>20-081</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 5257</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Poland</country>
  </location_countries>
  <link>
    <url>http://ctr.bms.com/ctd/start.do</url>
    <description>BMS Clinical Trials Disclosure</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 23, 2014</lastchanged_date>
  <firstreceived_date>June 28, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
